BioVie Inc.BIVINASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
139.83%
↓ 69% below average
Average (39q)
452.25%
Historical baseline
Range
High:16512.31%
Low:-97.64%
Volatility
3672.7%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 139.83% |
| Q2 2025 | -8.97% |
| Q1 2025 | -71.41% |
| Q4 2024 | 136.40% |
| Q3 2024 | -3.11% |
| Q2 2024 | -63.97% |
| Q1 2024 | -11.90% |
| Q4 2023 | -27.10% |
| Q3 2023 | 6.94% |
| Q2 2023 | -25.87% |
| Q1 2023 | 59.21% |
| Q4 2022 | 3.88% |
| Q3 2022 | 15.28% |
| Q2 2022 | 64.17% |
| Q1 2022 | -24.11% |
| Q4 2021 | 52.31% |
| Q3 2021 | -97.64% |
| Q2 2021 | 16512.31% |
| Q1 2021 | -15.83% |
| Q4 2020 | 829.60% |
| Q3 2020 | -31.56% |
| Q2 2020 | -58.25% |
| Q1 2020 | 1.93% |
| Q4 2019 | 1.47% |
| Q3 2019 | 23.85% |
| Q2 2019 | -16.91% |
| Q1 2019 | 61.07% |
| Q4 2018 | 5.91% |
| Q3 2018 | 103.18% |
| Q2 2018 | 106.24% |
| Q1 2018 | -75.16% |
| Q4 2017 | 346.41% |
| Q3 2017 | -53.74% |
| Q2 2017 | -24.63% |
| Q1 2017 | -6.62% |
| Q4 2016 | 1.01% |
| Q3 2016 | 235.80% |
| Q2 2016 | 0.00% |
| Q1 2016 | 0.00% |
| Q4 2015 | 0.00% |